Importantly, ADAMTSL5 confers tumorigenicity by upregulating oncogenic inputs (i.e., MET, EGFR, PDGFRβ, IGF1Rβ, FGFR4), and its abrogation increases sensitivity of tumor cells to clinically relevant drugs (45). This evidence concerns the gene ADAMTSL5 and neoplasm.